https://zhibo.sina.com.cn/gd/ty50024970

On March 26, 2025, the China-US Great Healthcare Industry Investment M&A Alliance Summit Forum was grandly held in Macau, focusing on global trends in healthcare industry investment and mergers and acquisitions. The forum brought together world-leading biotechnology and healthcare experts, industry leaders, and investment institutions to discuss hot topics such as the internationalization and modernization of traditional Chinese medicine (TCM) and TCM large-scale models. The event featured keynote speeches by academicians, roundtable discussions, and other sessions, aiming to promote cross-sector collaboration and innovative development in the healthcare industry while providing a platform for enterprises to showcase and explore partnerships.

Mr. Qiu Hesong, President of Jiying Technology, emphasized during the roundtable forum on the innovation of traditional Chinese medicine and artificial intelligence that Jiying Technology remains committed to the deep integration of AI and healthcare. He expressed his honor and gratitude for the invitation to share insights.

Originating in Xiamen and expanding to Hong Kong, Jiying Technology has, after years of development, established partnerships with over a dozen countries. To date, the company has successfully completed the entire process—from development to implementation—for seven AI-related products. Among them, the AI-assisted diagnostic system for early gastrointestinal cancer screening has been deployed in multiple medical institutions. Additionally, the company's Helicobacter pylori detection project has received support and guidance from Professor Marshall.

Leveraging AI technology, Jiying Technology has also built a comprehensive medical service platform covering "home testing → hospital diagnosis → post-diagnosis management." This platform addresses the critical challenge in traditional healthcare where doctors struggle to track patients' conditions in real time, thereby enhancing the continuity and precision of medical services.

Mr. Qiu Hesong shared at the forum that he ventured into the field of digitalizing traditional Chinese medicine (TCM) several years ago. However, due to insufficient recognition from the West regarding the scientific validation of TCM, the team resolutely shifted toward a more rigorous research and development path.

In recent years, leveraging artificial intelligence technology, the team has successfully integrated TCM's empirical medical data with scientific data to establish the "AI Drug Efficacy Screening and Functional Food Development Platform." This platform aids the TCM industry in transitioning from experience-driven practices to data-driven science. Equipped with robust computing power, it conducts large-scale drug simulations and employs data science methodologies to perform precise analyses of TCM functions while developing targeted strategies for gene regulation.

This approach not only significantly shortens traditional validation cycles but also markedly enhances the accuracy and efficiency of TCM development. Currently, the platform has preliminarily identified 1-2 active monomeric components based on TCM theories, with related research advancing intensively.